Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980,Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Contact
Amgen Switzerland AG
Dammstrasse 21
Postfach 1459
CH-6301 train
Tel: +41 41 369 01 00
Amgen (Europe) GmbH
Dammstrasse 23
Postfach 1557
CH-6301 train
Tel: +41 41 369 03 00
Myriam DeLeone, General Manager of Amgen Switzerland, discusses the company’s commitment to tackling diseases prevalent in Switzerland such cardiovascular diseases and osteoporosis, Amgen’s expanding biosimilars profile, and how the company is…
In a wide-ranging interview, Henrik Asmussen outlines his priorities for Amgen’s important Swiss affiliate, market access and pricing challenges, the company’s exciting pipeline, and what makes Amgen Switzerland a great…
Thomas Seewoester, Vice President Site Operations and Site Head at Amgen Manufacturing Limited, LLC, has overseen Puerto Rico’s most significant manufacturing campus for three years, building on more than three…
When, in his 2023 policy address, Hong Kong Chief Executive John Lee announced the territory’s intention to conduct its own primary reviews of medicines, the initial industry reaction was mixed.…
It is not unreasonable, at first glance, to ask why so many pharma multinationals have chosen to establish standalone affiliates in Hong Kong. After all, only 7.5 million people call…
Amgen’s trajectory in Hong Kong reflects a broader shift underway across the territory’s healthcare landscape, where data-driven care and cross-sector collaboration are converging to accelerate access to innovation. Against the…
France may have ceded Europe’s top spot for the sheer number of clinical trial starts to Spain in 2023, but it remains one of Europe’s most strategically valuable destinations for…
France has long been held up as Europe’s reference point for rare disease care – the first EU country with a national plan, a pioneer of coordinated expert networks, and…
With over 35 years of experience across major pharmaceutical markets, Corinne Blachier-Poisson, General Manager of Amgen France, she discusses Amgen France’s ambitions and the company’s pivotal role in shaping France’s…
Puerto Rico’s healthcare system is a paradox of strength and fragility. With one of the highest insurance coverage rates in the US (around 94 percent) and a long tradition of…
Glorimar Torres, with over 33 years in the pharmaceutical industry, has had a diverse career, starting as a sales representative in Puerto Rico and progressing through key roles at companies…
Saudi Arabia’s pharmaceutical sector continues its impressive growth leadership within the region. With a 9.1 percent market growth in 2024 and a projected USD 11.6 billion in sales, the Kingdom…
Rare diseases, by definition, only affect small patient populations. However, when the more than 7,000 known rare conditions are taken together, their impact on health, societies, and economies is enormous.…
Lyes Salah, General Manager of Amgen Saudi Arabia, delves into the company’s commitment to supporting Saudi Vision 2030 through innovation, strategic partnerships, and talent development. By advancing healthcare accessibility, fostering…
See our Cookie Privacy Policy Here
